Earnings Summary

Biomarin Pharmaceutical Inc.’s revenue jumped 111416.9% since last year same period to $595275Mn in the Q2 2023. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 99708.86% jump in its revenue since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit jumped 202473.74% since last year same period to $56040Mn in the Q2 2023. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 110102.16% jump in its net profits since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit margin jumped 81.65% since last year same period to 9.41% in the Q2 2023. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated 10.41% jump in its net profit margins since last 3-months.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.07 - a -600% fall from last quarter’s estimates.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -0.07.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biomarin Pharmaceutical Inc.’s return on assets (ROA) stands at 0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biomarin Pharmaceutical Inc.’s return on equity (ROE) stands at 0.02.